Navigation Links
Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the National Academy of Sciences (1) supports the findings of several other studies that EpCAM (CD326), which is used as the target for Micromet's product candidates adecatumumab (MT201) and MT110, may be suitable as a target for eradication of so called "cancer stem cells" (CSCs). The other studies showed that CSCs from colon (2), breast (3), pancreatic (4) and prostate (5) cancers all express high levels of EpCAM, which, according to these studies, makes these cells particularly capable of causing tumors.

CSCs constitute a small percentage of tumor cells that have the potential to self-renew and to permanently repopulate a tumor with new cancer cells. CSCs appear to be resistant to various chemotherapies, which may be one of the key reasons why most current therapies cannot cure cancer through elimination of all tumor cells (6). Micromet scientists believe that the findings of EpCAM expression by CSCs in many cancers and of EpCAM being a frequently and highly expressed tumor-associated antigen (7, 8), supports Micromet's use of EpCAM for targeted therapeutics.

EpCAM is the target for Micromet's clinical-stage product candidate adecatumumab (MT201), a fully human monoclonal antibody being co-developed with Merck Serono. In addition, Micromet's BiTE(R) product candidate MT110, an anti-EpCAM/CD3-bispecific antibody construct, is currently in late preclinical development. Both product candidates are designed to recognize EpCAM- expressing cancer cells and to instruct cytotoxic cells of the immune system to eliminate such cancer cells.

"The 'seek and destroy' mechanism of our EpCAM-directed therapeutic drug can
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:8/4/2015)... and LOS ANGELES , Aug. ... DGX ), the world,s leading provider of diagnostic ... the previously announced acquisition of MemorialCare Health System,s ... a result of the transaction, patients and physicians ... innovative services and network of nearly 200 patient ...
(Date:8/4/2015)... , Aug. 4, 2015  The Pittsburgh Life Sciences ... firm, announced today that one of its portfolio companies, ... their Flex ® Robotic System in the U.S.  ... more proud of Medrobotics," said John W. Manzetti ... a very long way since spinning out of The ...
(Date:8/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... $18.9 million for the three and six months ended ... of $12.1 million and $43.4 million for the same ... driven primarily by the more than $90 million of ... the upfront payment from Bayer to license  ISIS-FXI Rx ...
Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Members receiving ... quality care metrics – at a cost that is nine percent lower -- than ... Cross Blue Shield of New Jersey’s patient-centered programs. , “The promise of patient-centered, ...
(Date:8/4/2015)... ... ... They say a picture is worth a thousand words, and when it ... be essential. StayWell, a health solutions company, announced today it will license KramesArt™ for ... by physicians and other health care providers for more than 40 years and are ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... with “Dr. Google” before calling a physician. In an effort to share more ... health care provider in Pennsylvania to publicly share patient satisfaction ratings and comments ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... design, product packaging, and fulfillment services, joined over 200 other Long Island-based corporations ... held on Tuesday, July 28th at Jones Beach State Park in Wantagh, New ...
(Date:8/4/2015)... ... August 04, 2015 , ... Patients ... now offered by the world renowned Beverly Hills facelift surgeon , Dr. ... cosmetic surgery techniques helps individuals to achieve an outer appearance that meets their ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3
... WASHINGTON, June 4 As talk of ... sales bring up,worries about the nation,s economic health, ... are stressed and anxious about,their financial future. An ... that,two-thirds (66 percent) of Americans identify the economy ...
... fall out as a result of inflammation and subsequent ... Agnes Berendsen has investigated a possible solution to this ... she has studied the regeneration of the periodontal ligament ... model she has developed appears to be promising for ...
... such as periods of high temperature, is one way ... like cryptosporidiosis, an intestinal disease that causes upset stomach ... model that takes into account weather and other factors ... ill during an outbreak. With this model they show ...
... 4, 2008 -- Bioengineers at Rice University have discovered ... experience more than a half-mile beneath the ocean,s surface ... nearly all of the properties of natural cartilage. The ... provide relief for thousands of arthritis sufferers. , "This ...
... DALLAS June 3, 2008 Young adults who abuse ... attack, UT Southwestern Medical Center researchers have found. , In ... Alcohol Dependence , researchers examined data from more than 3 ... 2000 through 2003 in Texas and found a relationship between ...
... who took part in two health surveys carried out a ... published in the latest Journal of Advanced Nursing. , Thirteen ... second survey and a further five per cent reported problems ... were more likely to report multiple psychological problems and health ...
Cached Medicine News:Health News:Economy and Money Top Causes of Stress for Americans 2Health News:Economy and Money Top Causes of Stress for Americans 3Health News:Saving teeth by using periodontal ligament regeneration 2Health News:Weather, stomach bugs and climate change: Refining the model 2Health News:Cartilage regeneration '20,000 Leagues Under the Sea' 2Health News:Cartilage regeneration '20,000 Leagues Under the Sea' 3Health News:Study finds link between amphetamine abuse and heart attacks in young adults 2Health News:Nearly 1 in 5 teenagers admit eating problems, but anxiety is a bigger problem than appearance 2
Microforceps: Spaid Pic Forceps...
End-gripping forceps with small, concentric rings on each tip. For general purpose membrane grasping, particularly thin membranes, or grasping membranes adherent to the retinal surface....
... design and developmerit of systems for the ... is pleased to present its latest system ... in one compact system. The D.O.R.C. VFI/VFE ... such as silicone oil, with viscosities of ...
... System provides the bright, white illumination ... remarkable difference: HEXON utilizes a metal ... source of high quality illumination. This ... consistency which is well suited for ...
Medicine Products: